Double maintains 1 strategies that include NUVL - Nuvalent, Inc.
Yahoo
Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential. On June 24, Nuvalent announced positive pivotal data from its global ARROS-1 Phase 1/2 clinical trial for zidesamtinib. The novel ROS1-selective inhibitor is being developed for TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-small cell lung cancer/NSCLC. […]
Yahoo
Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities analyst Silvan Tuerkcan maintained a “Market Outperform” rating on Nuvation’s stock on June 25. The analyst also kept the price target at $6.00 per share. Tuerkcan’s decision follows Nuvation’s detailed presentation of launch plans for […]
Yahoo
Leerink raised the firm’s price target on Nuvalent (NUVL) to $140 from $125 and keeps an Outperform rating on the shares. Nuvalent’s zidesamtinib has demonstrated a best in class profile in the competitive ROS1 landscape, driven by “unprecedented” durability and tolerability-attributes that have limited the commercial success of other ROS1 agents, the analyst tells investors in a research note. Leerink believes the drug has the potential to be a blockbuster in ROS1+ tumors across all lines of th
Yahoo
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Nuvalent (NUVL) to $130 from $110 and keeps a Buy rating on the shares. The company reported positive topline results from the Phase 1/2 ARROS-1 study evaluating zidesamtinib to treat ROS1-positive non-small cell lung cancer patients that have received prior (tyrosine kinase inhibitor therapy, the analyst tells investors in a research note. The firm says the overall response rate among all patients is 44%, and the p
Yahoo
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced positive pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) from the global ARROS-1 Phase 1/2 clinical trial.
Yahoo
New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung cancer, a crowded indication with uncertain sales potential.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 60.22% | $4.81B | 0.35% |
| IBB | 54.84% | $5.37B | 0.45% |
| GNOM | 52.38% | $46.47M | 0.5% |
| PTH | 51.58% | $96.25M | 0.6% |
| PBE | 49.82% | $226.91M | 0.58% |
| FBT | 49.33% | $1.02B | 0.54% |
| ARKG | 49.21% | $1.03B | 0.75% |
| IWO | 49.18% | $11.77B | 0.24% |
| XPH | 48.49% | $150.58M | 0.35% |
| IWC | 48.22% | $840.86M | 0.6% |
| VTWO | 48.09% | $12.65B | 0.07% |
| IWM | 47.89% | $65.64B | 0.19% |
| SCHA | 47.22% | $17.61B | 0.04% |
| BBH | 47.19% | $339.54M | 0.35% |
| KJAN | 46.96% | $279.50M | 0.79% |
| KJUL | 46.93% | $159.39M | 0.79% |
| ISCG | 46.86% | $688.57M | 0.06% |
| ESML | 46.47% | $1.88B | 0.17% |
| VBK | 46.36% | $19.19B | 0.07% |
| TMSL | 46.36% | $851.11M | 0.55% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -32.74% | $315.93M | 1.43% |
| TAIL | -32.16% | $94.86M | 0.59% |
| VIXY | -32.06% | $184.73M | 0.85% |
| IVOL | -17.12% | $342.69M | 1.02% |
| FTSD | -16.94% | $233.11M | 0.25% |
| KCCA | -14.66% | $108.37M | 0.87% |
| ULST | -12.46% | $592.38M | 0.2% |
| TFLO | -11.71% | $6.74B | 0.15% |
| XONE | -11.36% | $628.85M | 0.03% |
| UTWO | -8.65% | $376.33M | 0.15% |
| CTA | -8.39% | $1.08B | 0.76% |
| SPTS | -8.23% | $5.77B | 0.03% |
| STOT | -8.12% | $252.82M | 0.45% |
| WEAT | -7.86% | $123.28M | 0.28% |
| XHLF | -7.73% | $1.73B | 0.03% |
| AGZD | -7.51% | $98.56M | 0.23% |
| TPMN | -6.64% | $31.06M | 0.65% |
| FXY | -6.61% | $802.69M | 0.4% |
| USFR | -6.36% | $18.61B | 0.15% |
| SCHO | -6.36% | $10.98B | 0.03% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CGON | 54.56% | $2.07B | -21.33% | 0.00% |
| CRNX | 50.44% | $3.00B | -39.42% | 0.00% |
| RVMD | 49.25% | $7.17B | -11.19% | 0.00% |
| IDYA | 48.97% | $2.00B | -42.45% | 0.00% |
| KYMR | 48.94% | $3.17B | +15.92% | 0.00% |
| ROIV | 47.99% | $7.87B | +2.94% | 0.00% |
| NRIX | 47.94% | $965.91M | -42.49% | 0.00% |
| XNCR | 46.57% | $660.47M | -52.14% | 0.00% |
| DNLI | 46.41% | $2.23B | -33.52% | 0.00% |
| XENE | 45.57% | $2.53B | -19.91% | 0.00% |
| LSCC | 44.94% | $7.55B | -6.43% | 0.00% |
| IMVT | 44.86% | $2.99B | -42.32% | 0.00% |
| RNA | 43.76% | $3.79B | -28.98% | 0.00% |
| COGT | 43.29% | $1.24B | +18.71% | 0.00% |
| OCUL | 43.27% | $1.77B | +45.79% | 0.00% |
| KRYS | 42.59% | $4.33B | -24.53% | 0.00% |
| ELVN | 42.53% | $1.34B | -5.32% | 0.00% |
| APGE | 42.43% | $2.30B | -16.02% | 0.00% |
| ATXS | 42.24% | $376.42M | -40.71% | 0.00% |
| IRON | 42.23% | $2.01B | +23.64% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| AGZ | -0.04% | $609.66M | 0.2% |
| GBIL | -0.06% | $6.36B | 0.12% |
| VGIT | 0.17% | $31.63B | 0.04% |
| CLIP | -0.23% | $1.55B | 0.07% |
| IBTJ | -0.39% | $686.15M | 0.07% |
| IBTK | -0.51% | $445.94M | 0.07% |
| IBMN | 0.66% | $445.23M | 0.18% |
| SCHR | 0.66% | $10.79B | 0.03% |
| BILZ | -0.79% | $851.85M | 0.14% |
| NEAR | 0.82% | $3.35B | 0.25% |
| UDN | 0.95% | $147.46M | 0.78% |
| IBTL | 0.96% | $381.26M | 0.07% |
| YEAR | 0.97% | $1.46B | 0.25% |
| VTIP | 0.97% | $15.15B | 0.03% |
| FXE | 1.00% | $588.06M | 0.4% |
| TYA | 1.02% | $147.35M | 0.15% |
| BIL | 1.02% | $41.93B | 0.1356% |
| TBLL | -1.03% | $2.12B | 0.08% |
| BSV | 1.13% | $37.89B | 0.03% |
| IBTM | 1.21% | $316.60M | 0.07% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LITB | -13.51% | $24.26M | -71.62% | 0.00% |
| MO | -8.79% | $98.62B | +24.36% | 7.00% |
| K | -7.75% | $27.64B | +40.17% | 2.86% |
| CME | -7.70% | $99.17B | +44.04% | 1.75% |
| KR | -7.57% | $46.75B | +34.05% | 1.81% |
| NEUE | -7.19% | $60.71M | +34.39% | 0.00% |
| AGL | -6.88% | $956.23M | -62.44% | 0.00% |
| CBOE | -6.43% | $24.55B | +38.09% | 1.08% |
| LRN | -6.19% | $5.92B | +101.30% | 0.00% |
| VSA | -6.00% | $8.59M | -17.17% | 0.00% |
| ED | -5.18% | $36.42B | +10.51% | 3.36% |
| VSTA | -5.01% | $325.62M | +30.97% | 0.00% |
| ACI | -4.96% | $12.57B | +13.79% | 2.42% |
| AWK | -4.15% | $27.82B | +4.74% | 2.18% |
| STG | -3.19% | $38.79M | -3.01% | 0.00% |
| BMRN | -2.24% | $11.28B | -29.90% | 0.00% |
| CCEC | -2.14% | $1.02B | +3.91% | 2.48% |
| ICL | -2.12% | $9.14B | +60.54% | 2.66% |
| ALHC | -2.00% | $2.65B | +51.87% | 0.00% |
| GNE | -1.83% | $612.08M | +42.14% | 1.33% |
Current Value
$81.301 Year Return
Current Value
$81.301 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PLCE | -0.06% | $114.61M | -46.03% | 0.00% |
| CARV | -0.16% | $9.39M | +24.99% | 0.00% |
| EXC | 0.16% | $44.05B | +23.53% | 3.60% |
| MKTX | 0.16% | $8.21B | +2.36% | 1.37% |
| FIZZ | 0.30% | $4.21B | -10.24% | 0.00% |
| TU | -0.35% | $25.21B | +7.34% | 6.98% |
| TPB | 0.51% | $1.30B | +101.13% | 0.40% |
| ZCMD | 0.65% | $28.54M | -8.87% | 0.00% |
| HRTG | 0.74% | $661.40M | +211.08% | 0.00% |
| CYCN | -0.81% | $11.40M | +5.03% | 0.00% |
| HSY | -0.88% | $33.36B | -11.86% | 3.35% |
| FUBO | -0.98% | $1.19B | +173.23% | 0.00% |
| LTM | -0.98% | $12.85B | -95.43% | 2.39% |
| MCK | -1.00% | $89.25B | +24.22% | 0.40% |
| CREG | 1.01% | $5.91M | -76.05% | 0.00% |
| COR | 1.08% | $57.63B | +33.93% | 0.73% |
| VZ | 1.09% | $177.21B | +1.77% | 8.05% |
| GO | -1.24% | $1.26B | -39.10% | 0.00% |
| AIFU | -1.24% | $17.40M | +87.81% | 0.00% |
| DOGZ | 1.29% | $117.12M | -40.72% | 0.00% |
